Very lately, preliminary benefits from a 3rd demo evaluating ibrutinib versus observation had been offered.one hundred and five Patients receiving ibrutinib had a longer occasion-cost-free survival, but no Over-all survival gain, Even though the results ended up continue to immature. Furthermore, Th